 After hinting at ongoing negotiations for larger vaccine deals on its earnings call, Moderna Inc (NASDAQ: MRNA) said late Tuesday that it signed an agreement with the U.S. government to supply 100 million doses of its coronavirus vaccine candidate mRNA-1273 for $1.525 billion.The Moderna Analysts: SVB Leerink analyst Mani Foroohar maintained a Market Perform rating on Moderna shares and lowered the price target from $60 to $58. Chardan analyst Geulah Livshits maintained a Buy rating and $95 price target.Morgan Stanley analyst Matthew Harrison maintained an Overweight rating and $90 price target.SVB Leerink Sees Long-Term Pricing Risk: The contract award from the U.S. government implies a price of $15.25 per dose, materially below the previously modeled $22 per dose, as well as the Pfizer Inc. (NYSE: PFE)/BioNTech SE - ADR (NASDAQ: BNTX) combine's $19.50 per-dose pricing for the government contract, Foroohar said in a Wednesday note.Moderna's contract with the U.S. government includes incentive payments for timely delivery, with some portion of the pricing at risk if the company is not able to obtain emergency use authorization or BLA approval by Jan. 31, 2021, the analyst said. An EUA by this timeframe is likely, given the flexibility of regulatory agencies with respect to SARS-CoV-2 vaccine candidates, he said. Even this assumption carries a risk if Moderna experiences a delay in clinical trial execution or reports disappointing interim data from
|
Private Label